Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The MRC Anatomical Neuropharmacology Unit at the University of Oxford (MRC ANU) closed on the 31 March after 30 years of world leading research on the complex networks of the brain. From 1 April, the ANU becomes  the Medical Research Council Brain Network Dynamics Unit at the University of Oxford (MRC BNDU). 

Our goal is to understand and exploit the interactions between nerve cells that are critical for brain functions, with a special focus on the brain circuits underlying movement and memory...we aim to develop and deliver novel therapies that specifically target the disturbed circuit interactions arising in disease.
- Professor Peter Brown

The new unit, led by director Professor Peter Brown, will build on the previous unit's success, using animal models and patients to understand brain circuitry in some of the most prevalent and debilitating brain disorders such as Parkinson’s disease, memory disorders and Alzheimer’s disease.

The MRC BNDU will be uniquely multidisciplinary and integrate research programmes covering clinical, experimental and computational neuroscience in both the Department of Pharmacology and the Nuffield Department of Clinical Neurosciences.

Read more...

Similar stories

Bioelectronic implant offers an intelligent therapy to treat incontinence

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their 'smart' bioelectronic implants.

Direct evidence of reduced NMDA receptors in people with form of encephalitis

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.